Who we are

We are enthusiastic about cancer research. Our goal is to contribute to better outcomes for cancer patients by focussing our research efforts in two main areas. We develop novel immunotherapeutic approaches in hematological cancers and solid tumors and we use liquid biopsies to understand the cancer genome and measure treatment response in cancer patients at high resolution.

Publications

Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR

Jan-Michel Heger, Yannick d'Hargues, Fanni Kleinert, Julia Mattlener, Jonathan Weiss, Fabian Franzen, Christian Becker, Kerstin Becker, Philipp Gödel, Marcel Schmiel, Jörn Meinel, Ruth Flümann, Florian Simon, H Christian Reinhardt, Peter Borchmann, Sven Borchmann, Hyatt Balke-Want, Gero Knittel, Bastian von Tresckow

European Journal of Haematology

Human leukocyte antigen (HLA) class I expression on Hodgkin-Reed-Sternberg cells is an EBV-independent major determinant of microenvironment composition in classic Hodgkin lymphoma

Berit Müller-Meinhard, Nicole Seifert, Johanna Grund, Sarah Reinke, Fatih Yalcin, Helen Kaul, Sven Borchmann, Bastian von Tresckow, Peter Borchmann, Annette Plütschow, Julia Richter, Andreas Engert, Michael Altenbuchinger, Paul J Bröckelmann, Wolfram Klapper

Hemasphere, 2024

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

Conrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, Jan-Michel Heger, Beatrice Casadei, Laura Beckmann, Ken Herrmann, Franziska J Dekorsy, Nadine Kutsch, Peter Borchmann, Stefano Fanti, Wolfgang G Kunz, Marion Subklewe, Carsten Kobe, Pier Luigi Zinzani, Matthias Stelljes, Katrin S Roth, Alexander Drzezga, Richard Noppeney, Kambiz Rahbar, H Christian Reinhardt, Bastian von Tresckow, Robert Seifert, Jörn C Albring, Viktoria Blumenberg, Andrea Farolfi, Sarah Flossdorf, Philipp Gödel, Christine Hanoun

European Journal of Nuclear Medicine and Molecular Imaging, 2024

Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T-cell therapy

Dennis A Eichenauer, Jan-Michel Heger, Isabel Kruschel, Nadine Kutsch, Philipp Gödel, Jorge Garcia Borrega, Ulf Schnetzke, Boris Böll, Marie Anne-Catherine Neumann, Cordula Gebel, Anne Pralong, Peter Borchmann, Raymond Voltz, Ulrich Wedding, Steffen T Simon

British Journal of Haematology, 2024

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Jan-Michel Heger, Julia Mattlener, Jessica Schneider, Philipp Gödel, Noëlle Sieg, Fabian Ullrich, Richard Ian Lewis, Teodora Bucaciuc-Mracica, Roland F. Schwarz, Daniel Rueß, Maximilian I Ruge, Manuel Montesinos-Rongen, Martina Deckert, Tobias Blau, Nadine Kutsch, Hyatt Balke-Want, Jonathan Weiss, Kerstin Becker, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann

Blood, 2024

View all

Ongoing projects

Liquid Biopsies

Liquid biopsies allow for easy sampling of a cancer’s genome by a simple blood draw. This not only enables access to crucial molecular information in patients that have difficult-to-biopsy lesions, but it also provides an opportunity to gain insight i...

Translational Research in Hodgkin Lymphoma

In close ties with the German Hodgkin Study Group (GHSG) we archive biomaterials form Hodgkin lymphoma patients within GHSG clinical trials. Building on this large collection of materials we are conducting translational studies to deepen our understan...

Cancer Microbiome

A further axis of our research is the response of the human host to acute and chronic infection and how this response can shape cancer development secondary to infection. We have comprehensively characterized bacterial and viral genomes in over 3000 w...

Bispecific Antibody Development

Transfer or induction of neo- or tumour-associated antigen specific T-cells can be a core element of successful immunotherapy. However, clinical translation of adoptive cell therapy is technically difficult, expensive, and associated with high regulato...

Drug Repurposing for Immunotherapy

Another focus of our research is drug repurposing for cancer immunotherapy. While drug repurposing (the use of already approved drugs in novel indications) has a long history in oncology, it has so far not been studied sufficiently in cancer immunothe...